doi:10.3969/j.issn.1004-583X.2023.07.013

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.07.013

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I7/659

References 35

[1]	World Health Organization. Global tuberculosis report 2019[R]. Geneva: WHO: 2019.
[2]	Natarajan A, Beena PM, Devnikar AV, et al. A systemic review on tuberculosis[J]. Indian J Tuberc, 2020, 67(3):295-311. doi: S0019-5707(20)30030-5 pmid: 32825856
[3]	米洁, 薛勇, 白雪娟, 等. 淋巴细胞亚群检测在结核病诊疗中的应用进展[J]. 中国防痨杂志, 2021, 43(2):178-185.
[4]	Nakajima M, Matsuyama M, Kawaguchi M, et al. Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium[J]. Sci Rep, 2021, 11(1):18008. doi: 10.1038/s41598-021-97391-4 pmid: 34504192
[5]	Sia JK, Rengarajan J. Immunology of mycobacterium tuberculosis infections[J]. Microbiol Spectr, 2019, 7(4):10.
[6]	Marasco M, Berteotti A, Weyershaeuser J, et al. Molecular mechanism of SHP2 activation by PD-1 stimulation[J]. Sci Adv, 2020, 6(5):eaay4458. doi: 10.1126/sciadv.aay4458 URL
[7]	Shen L, Gao Y, Liu Y, et al. PD-1/PD-L pathway inhibits M.tb-specific CD4⁺ T-cell functions and phagocytosis of macrophages in active tuberculosis[J]. Sci Rep, 2016, 6:38362. doi: 10.1038/srep38362 pmid: 27924827
[8]	Day CL, Abrahams DA, Bunjun R, et al. PD-1 Expression on mycobacterium tuberculosis-specific CD4 T cells is associated with bacterial load in human tuberculosis[J]. Front Immunol, 2018, 9:1995. doi: 10.3389/fimmu.2018.01995 URL
[9]	Liu X, Li F, Niu H, et al. IL-2 restores T-cell dysfunction induced by persistent mycobacterium tuberculosis antigen stimulation[J]. Front Immunol, 2019, 10:2350. doi: 10.3389/fimmu.2019.02350 URL
[10]	Shen L, Shi H, Gao Y, et al. The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis[J]. Tuberculosis (Edinb), 2016, 101:146-150. doi: 10.1016/j.tube.2016.10.001 URL
[11]	Yang C, Dai F, Pulati R, et al. Clinical significance of negative costimulatory molecule PD-1/PD-L1 on peripheral blood regulatory T cell levels among patients with pulmonary tuberculosis[J]. J Trop Med, 2022, 2022:7526501.
[12]	Haddadi MH, Negahdari B. Clinical and diagnostic potential of regulatory T cell markers: From bench to bedside[J]. Transpl Immunol, 2022, 70:101518. doi: 10.1016/j.trim.2021.101518 URL
[13]	Khalili A, Ebrahimpour S, Maleki I, et al. CD4⁺CD25⁺CD127low Foxp3⁺ regulatory T cells in Crohn's disease[J]. Rom J Intern Med, 2018, 56(3):158-166. doi: 10.2478/rjim-2018-0006 pmid: 29453928
[14]	Grover P, Goel PN, Greene MI. Regulatory T cells: Regulation of identity and function[J]. Front Immunol, 2021, 12:750542. doi: 10.3389/fimmu.2021.750542 URL
[15]	Suarez GV, Melucci Ganzarain CDC, Vecchione MB, et al. PD-1/PD-L1 pathway modulates macrophage susceptibility to mycobacterium tuberculosis specific CD8⁺ T cell induced death[J]. Sci Rep, 2019, 9(1):187. doi: 10.1038/s41598-018-36403-2
[16]	Li J, Jin C, Wu C, et al. PD-1 modulating mycobacterium tuberculosis-specific polarized effector memory T cells response in tuberculosis pleurisy[J]. J Leukoc Biol, 2019, 106(3):733-747. doi: 10.1002/JLB.MA1118-450RR URL
[17]	Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases[J]. Nat Rev Immunol, 2018, 18(2):91104.
[18]	Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382):1350-1355. doi: 10.1126/science.aar4060 pmid: 29567705
[19]	Singh A, Mohan A, Dey AB, et al. Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis[J]. Clin Exp Immunol, 2017, 187(2):269-283. doi: 10.1111/cei.12871 pmid: 27665733
[20]	Kauffman KD, Sakai S, Lora NE, et al. PD-1 blockade exacerbates mycobacterium tuberculosis infection in rhesus macaques[J]. Sci Immunol, 2021, 6(55):eabf3861. doi: 10.1126/sciimmunol.abf3861 URL
[21]	Liu Q, Ou Q, Shen L, et al. BATF potentially mediates negative regulation of PD-1/PD-Ls pathway on T Cell functions in mycobacterium tuberculosis Infection[J]. Front Immunol, 2019, 10:2430. doi: 10.3389/fimmu.2019.02430 URL
[22]	Tousif S, Singh Y, Prasad DV, et al. T cells from programmed death-1 deficient mice respond poorly to mycobacterium tuberculosis infection[J]. PLoS One, 2011, 6(5):e19864. doi: 10.1371/journal.pone.0019864 URL
[23]	Barber DL, Mayer-Barber KD, Feng CG, et al. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition[J]. J Immunol, 2011, 186(3):1598-1607. doi: 10.4049/jimmunol.1003304 pmid: 21172867
[24]	Sakai S, Kawamura I, Okazaki T, et al. PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with mycobacterium bovis bacillus calmette-guérin[J]. Int Immunol, 2010, 22(12):915-925. doi: 10.1093/intimm/dxq446 pmid: 21047981
[25]	Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy[J]. Sci Transl Med, 2019, 11(475):eaat2702. doi: 10.1126/scitranslmed.aat2702 URL
[26]	Kawahara JY, Irvine EB, Alter G. A case for antibodies as mechanistic correlates of immunity in tuberculosis[J]. Front Immunol, 2019, 10:996. doi: 10.3389/fimmu.2019.00996 pmid: 31143177
[27]	Casadevall A. Antibody-based vaccine strategies against intracellular pathogens[J]. Curr Opin Immunol, 2018, 53:74-80. doi: S0952-7915(18)30018-9 pmid: 29704764
[28]	Rijnink WF, Ottenhoff THM, Joosten SA. B-cells and antibodies as contributors to effector immune responses in tuberculosis[J]. Front Immunol, 2021, 12:640168. doi: 10.3389/fimmu.2021.640168 URL
[29]	Singh A, Mohan A, Dey AB, et al. Inhibiting the programmed death 1 pathway rescues mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis[J]. J Infect Dis, 2013, 208(4):603-615. doi: 10.1093/infdis/jit206 pmid: 23661793
[30]	胥萍. PD-1/PD-L1在肺结核患者外周血淋巴细胞表面的表达特性及其生物学意义[C]. 江苏省第十八次感染病学学术会议论文集, 2016:78-78.
[31]	Albayrak N, Dirix V, Aerts L, et al. Differential expression of maturation and activation markers on NK cells in patients with active and latent tuberculosis[J]. J Leukoc Biol, 2022, 111(5):1031-1042. doi: 10.1002/JLB.4A1020-641RR URL
[32]	Kathamuthu GR, Kumar NP, Moideen K, et al. High dimensionality reduction and immune phenotyping of natural killer and invariant natural killer cells in latent tuberculosis-diabetes comorbidity[J]. J Immunol Res, 2022, 2022:2422790.
[33]	Junqueira-Kipnis AP, Trentini MM, Marques Neto LM, et al. Live vaccines have different NK cells and neutrophils requirements for the development of a protective immune response against tuberculosis[J]. Front Immunol, 2020, 11:741. doi: 10.3389/fimmu.2020.00741 pmid: 32391021
[34]	Hassan SS, Akram M, King EC, et al. PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment[J]. PLoS One, 2015, 10(9):e0137646. doi: 10.1371/journal.pone.0137646 URL
[35]	Alvarez IB, Pasquinelli V, Jurado JO, et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against mycobacterium tuberculosis[J]. J Infect Dis, 2010, 202(4):524-532. doi: 10.1086/654932 pmid: 20617899

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Lei, Li Mingwu, Wan Rong. Diagnostic value of laboratory indexes in patients with pulmonary tuberculosis complicated by pulmonary embolism [J]. Clinical Focus, 2024, 39(2): 134-139.
[2]	Liu Ye, Ruan Guiren, Liu Xiaoqing, Shi Xiaochun, Fei Guijun. Diagnosis and differential diagnosis of pancreatic tuberculosis [J]. Clinical Focus, 2023, 38(10): 898-903.
[3]	. [J]. Clinical Focus, 2023, 38(8): 737-742.
[4]	Wolazihan Madeniyati, Dilixiati Tuerdimaimaiti, Li Mengchen, Baihetinisha Tuerdi. Meta-analysis of the application value of metagenomic next-generation sequencing technology in the diagnosis of pulmonary tuberculosis [J]. Clinical Focus, 2023, 38(5): 389-398.
[5]	Luo Weigang, Yin Yuanyuan, Ren Huiling. Analysis and treatment of primary spinal infection [J]. Clinical Focus, 2022, 37(6): 525-529.
[6]	Xu Jingran, Li Feifei, Xie Chengxin, Gong Hui, Luan Qiyun, Li Li. Application of endobronchial ultrasound transbronchial lung biopsy with guide sheath and rapid on-site evaluation in the diagnosis of bacteriologically-negative pulmonary tuberculosis [J]. Clinical Focus, 2022, 37(3): 220-224.
[7]	. [J]. Clinical Focus, 2022, 37(2): 166-169.
[8]	Li Baiyuan, Li Yuanjun, Li Lingxia. Study of mobile phone dependence and sleep disorder in patients with pulmonary tuberculosis [J]. Clinical Focus, 2021, 36(8): 719-723.
[9]	Li Chaojun, Sun Chenghong, Jin Wenyu. Comparation of CT imaging characteristics between non-tuberculous mycobacterium tuberculosis and multi-drug resistant tuberculosis [J]. Clinical Focus, 2021, 36(6): 530-534.
[10]	Lu Haoyang, Lu Jiazhong, Han Mingfeng, Lvh Xincai, Zhang Biao, Rong Chengzhen, Jia Leilei, Pan Qiangqiang, Ma Leilei, Zhao Ren. Observations on clinical treatment of COVID-19 complicated with cardiovascular disease [J]. Clinical Focus, 2021, 36(3): 203-207.
[11]	. [J]. Clinical Focus, 2015, 30(12): 1427-1428.
[12]	. @@ [J]. Clinical Focus, 2015, 30(10): 1173-1175.
[13]	Lu Qingyun;Chen Wufei. Feasibility analysis of ultra low dose CT in follow-up physical examination population with solid pulmonary nodules [J]. Clinical Focus, 2015, 30(6): 637-640.
[14]	. [J]. Clinical Focus, 2015, 30(3): 319-321.
[15]	. [J]. Clinical Focus, 2015, 30(2): 214-216.